The goals of this proposal are to determine: a) the role of beta adrenergic receptors in hippocampal subregions in mediating antidepressant activity and the behavioral effects of noradrenergic antidepressants; and b) the relationship between changes in noradrenergic neurotransmission and the persistent behavioral effects that result from repeated treatment with noradrenergic antidepressants. To address these goals, four lines of investigation are proposed. First, it will be determined whether stimulation of beta-adrenergic receptors in subregions of the hippocampus produces antidepressant-like effects on behavior. This will be accomplished by determining the effects on DRL and forced-swim behavior of infusion of beta-adrenergic agonists and antagonists into subregions of the hippocampus (CA 1, CA2/CA3, dentate gyrus). Second, it will be determined whether beta-adrenergic receptors in subregions of the hippocampus mediate the behavioral effects of noradrenergic antidepressants. This will be accomplished by determining the ability of site-specific infusion of beta-adrenergic antagonists to block the effects of desipramine and reboxetine on DRL and forced swim behavior. Third, it will be determined whether the persistent behavioral effect on forced-swim behavior that occurs with repeated antidepressant treatment results from regulation of the norepinephrine transporter. This will be accomplished by comparing the dose-response and time-course of the behavioral effects with those for the regulation of the norepinephrine transporter produced by repeated treatment with desipramine or reboxetine. Fourth, it will be determined whether regulation of the norepinephrine transporter by repeated antidepressant treatment results in enhanced noradrenergic neurotransmission. This will be accomplished by comparing the dose-response and time-course of antidepressant-induced regulation of the norepinephrine transporter with those for increases in extracellular norepinephrine concentrations, measured using in vivo microdialysis. Completion of the proposed experiments will demonstrate the role that hippocampal beta-adrenergic receptors play in the mediation of antidepressant activity, particularly for those drugs thought to act via interactions with noradrenergic neurons. In addition, the manner by which adaptive changes in noradrenergic neurotransmission contribute to the development of persistent antidepressant effects will be elucidated. Overall, this work will provide new information relevant to the understanding of the pathophysiology and pharmacotherapy of depression. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH040694-21
Application #
7163028
Study Section
Special Emphasis Panel (ZRG1-IFCN-4 (06))
Program Officer
Winsky, Lois M
Project Start
1990-08-01
Project End
2008-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
21
Fiscal Year
2007
Total Cost
$312,545
Indirect Cost
Name
West Virginia University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
191510239
City
Morgantown
State
WV
Country
United States
Zip Code
26506
O'Donnell, James M; Xu, Ying (2012) Evidence for global reduction in brain cyclic adenosine monophosphate signaling in depression. Biol Psychiatry 72:524-5
Xiao, Lan; O'Callaghan, James P; O'Donnell, James M (2011) Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 338:641-7
Borysiewicz, Elizabeth; Fil, Daniel; Dlaboga, Daniel et al. (2009) Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes. Metab Brain Dis 24:481-91
Zhao, Zaorui; Zhang, Han-Ting; Bootzin, Elianna et al. (2009) Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology 34:1467-81
Masood, Anbrin; Huang, Ying; Hajjhussein, Hassan et al. (2009) Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 331:690-9
Zhang, Han-Ting; Whisler, Lisa R; Huang, Ying et al. (2009) Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology 34:1067-77
Zhang, Han-Ting; Huang, Ying; Masood, Anbrin et al. (2008) Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33:1611-23
Zhao, Zaorui; Baros, Alicia M; Zhang, Han-Ting et al. (2008) Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Neuropsychopharmacology 33:3190-200
Dlaboga, Daniel; Hajjhussein, Hassan; O'Donnell, James M (2008) Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology 54:745-54
Hajjhussein, Hassan; Suvarna, Neesha U; Gremillion, Carmen et al. (2007) Changes in NMDA receptor-induced cyclic nucleotide synthesis regulate the age-dependent increase in PDE4A expression in primary cortical cultures. Brain Res 1149:58-68

Showing the most recent 10 out of 36 publications